Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876841 | 0.88 | CYP1A2 (0.72) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL4876834 | 0.83 | TP53 (0.98) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL194768 | 0.82 | TP53 (1.00) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL4874880 | 0.80 | TP53 (0.70) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL4877646 | 0.78 | TP53 (0.84) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL4877735 | 0.78 | CYP3A4 (0.64) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL22899817 | 0.77 | TSHR (0.63) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5049558 | 0.76 | HTR1E (0.64) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL8584817 | 0.75 | TP53 (0.64) | TP53CYP1A2CYP3A4CYP2D6TSHR | |
| SCHEMBL5049482 | 0.75 | CYP1A2 (0.63) | TP53CYP1A2CYP3A4CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | claimed |
| EP-1797036-A1 | SIGMA RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2007-06-20 | — | — | EP | claimed |
| WO-2006027252-A1 | SIGMA RECEPTOR LIGANDS | UCB PHARMA, SA (BE) | 2006-03-16 | — | — | WO | claimed |
| US-20080153917-A1 | Sigma Receptor Ligands | UCB PHARMA, S.A. (BE) | 2008-06-26 | — | — | US | disclosed |
| EP-1797036-A1 | SIGMA RECEPTOR LIGANDS | UCB Pharma, S.A. (BE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006027252-A1 | SIGMA RECEPTOR LIGANDS | UCB PHARMA, SA (BE) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153917-A1 | Sigma Receptor Ligands | SIGMAR1, TMEM97, OPRL1 | TP53 4797/4885CYP1A2 141/4885CYP3A4 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.